EP
PLX icon

Essential Partners’s Protalix BioTherapeutics PLX Stock Holding History

Essential Partners’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189 Buy
81
+55
+212% +$116 ﹤0.01% 2650
2026
Q1 		$56 Buy
+26
New +$65 ﹤0.01% 2778

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Essential Partners's PLX Position: Q2 2026 in Review

Essential Partners increased its Protalix BioTherapeutics (PLX) stake by 212% in Q2 2026, buying an estimated $116 and bringing the position to 81 shares worth $189. The position accounts for ﹤0.01% of the portfolio, ranked #2650.

Essential Partners first reported a position in PLX in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Essential Partners held 81 shares of Protalix BioTherapeutics worth $189 as of Q2 2026.
  • Essential Partners bought 55 Protalix BioTherapeutics shares in Q2 2026, an estimated $116.
  • Protalix BioTherapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2650 holding.
  • Essential Partners first reported a position in Protalix BioTherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.